Last update Jan. 29, 2017
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Triprolidine Hydrochloride in other languages or writings:
Triprolidine Hydrochloride belongs to this group or family:
Main tradenames from several countries containing Triprolidine Hydrochloride in its composition:
|T½||3 - 5||hours|
|M/P ratio||0.5 - 1.2||-|
|Theoretical Dose||0.0002 - 0.0006||mg/Kg/d|
|Relative Dose||0.002 - 0.007||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
1st-generation-antihistamine and alkylamine-type drug with a moderate sedative effect.
It is excreted into breastmilk in a clinically non-significant amount with plasma levels that were undetectable or very low in infants whose mothers had received this medication (Findlay 1984).
First-generation antihistamines may decrease prolactin levels and interfere with milk production during the first few weeks after birth (Pontiroli 1981, Messinis 1985).
Monitor drowsiness and inadequate feeding on the infant.
It is not recommended bed-sharing if you are taking this medicine (UNICEF 2006, ABM 2008, Landa 2012, UNICEF 2013).
The American Academy of Pediatrics considers this medication as usually compatible with breastfeeding.